I wanted Biotech's view on this question about the technology...but he's not around or maybe not interested.
With an ex Oracle senior executive, and top scientists on the case, I don't think PSY is unprofessional, it is underfunded. They are entering the most expensive phase, the commercialisation phase and they are very squeezed financially. This affects their negotiating position.
This is where they either get a partner, sell licences to a high profile party or sell the technology to the highest bidder. Annoyingly their SP is nearly double ours.
ADO Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)